At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,710 enrolled
Drug / intervention
20vPnC +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE
In Brief
A Phase 3 clinical trial evaluating 20vPnC and 13vPnC for Pneumococcal Disease. Completed, enrolled 1,710 participants across 21 sites.
Detailed Summary
This is a Phase 3, randomized, double-blind study with a 4-arm parallel design. Adults 18 through 49 years of age with no history of pneumococcal vaccination will be randomized in a 2:2:2:1 ratio to receive a single dose of: 20vPnC Lot 1; 20vPnC Lot 2; 20vPnC Lot 3; or 13vPnC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartFeb 2019
Primary CompletionOct 2019
TodayJul 2026
First PostedFeb 4, 2019
Enrollment StartFeb 14, 2019
Primary CompletionOct 9, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.4 years ago
Interventions
20vPnCbiological
20vPnC
20vPnCbiological
20vPnC
20vPnCbiological
20vPnC
13vPnCbiological
Pneumococcal conjugate vaccine